Advanced Search
Contact | Corporate | Help

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Sponsors:
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Genentech
  • Sanofi-Synthelabo
  • Eli Lilly and Company
Phases:
  • Phase II
IndicationsAcronym:
  • Hepatocellular Carcinoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Gemcitabine
  • Drug: Oxaliplatin
  • Drug: Bevacizumab
Enrollment:
30

Additional information about NCT00142467.


SourceSolution © 2008-2012